81937-33-9

Usage

Classification

Nonsteroidal Anti-inflammatory Drug (NSAID)

Main Properties

+ Potent inhibitor of cyclooxygenase enzymes
+ Analgesic (pain-relieving) properties
+ Anti-inflammatory properties
+ Antipyretic (fever-reducing) properties

Specific Content

+ Used in veterinary medicine
+ Commonly used in horses and cattle
+ Treats musculoskeletal and soft tissue injuries
+ Manages postoperative pain
+ Reduces fever in animals with inflammatory conditions
+ Improves comfort in animals with endotoxemia and respiratory diseases
+ Effective and well-tolerated in animals
+ Valuable therapeutic option in veterinary medicine

Upstream product

• 78543-08-5 2-(4-amino-3-fluorophenyl)-2-methylmalonic acid diethyl ester 
• 446-35-5 2,4-Difluoronitrobenzene 
• 78543-06-3 diethyl 2-(3-fluoro-4-nitrophenyl)-2-methyl-malonate 
• 399-31-5 N-(2-fluorophenyl)acetamide 

Downstream Products

• 5104-49-4 fluorobiprofen 
• 90500-55-3 (±)-methyl 2-(4-amino-3-fluorophenyl)propanoate 
• 1402585-79-8 (±)-methyl 2-(3-fluoro-4-iodophenyl)propanoate 
• 1402585-80-1 C₁₂H₁₃FO₂ 
• 1402585-81-2 C₁₁H₁₁FO₂ 
• 5104-49-4 (S)-(+)-flurbiprofen 
• 5104-49-4 (R)-flurbiprofen 
• 1255040-62-0 4-[1-[[2-(3-chlorophenyl)-5-(trifluormethyl)-2H-pyrazol-3-yl]methylcarbamoyl]ethyl]-2-fluorobenzamide 
• 1402582-05-1 4-[1-[[2-(3-chlorophenyl)-5-(trifluoromethyl)-2H-pyrazol-3-yl]methylcarbamoyl]ethyl]-2-fluoro-N-(4-fluorophenyl)benzamide 
• 1402585-22-1 4-(1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methylamino)-1-oxopropan-2-yl)-2-fluorobenzoic acid 
• 1402585-21-0 N-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-2-(4-cyano-3-fluorophenyl)propanamide 
• 1402585-20-9 2-(4-cyano-3-fluorophenyl)propanoic acid 
• 1402585-19-6 ethyl 2-(4-cyano-3-fluorophenyl)propanoate 
• 1402585-18-5 ethyl 2-(3-fluoro-4-iodophenyl)propanoate 

Relevant academic research and scientific papers

Preparation method of flurbiprofen

The invention discloses a preparation method of flurbiprofen. The method comprises the following steps: adding 2-(3-fluoro-4-bromophenyl)propionic acid and phenylboronic acid into a water-system solvent under alkaline conditions, and carrying out a palladium-carbon catalyzed coupling reaction to obtain flurbiprofen. The method has the advantages that operation is simpler, the prepared flurbiprofenis higher in purity, industrialized production is facilitated.

Preparation method of flurbiprofen

The invention relates to a preparation method of flurbiprofen, and belongs to the technical field of medicine synthesis. In order to solve the problems of poor safety and low yield of the existing route, the invention provides a preparation method of flurbiprofen. The method comprises the following steps: under the action of Lewis acid, carrying out acylation reaction on o-fluoroaniline or N-substituted o-fluoroaniline and 2-halogenated propionyl halide to obtain an intermediate compound as shown in formula II; under the action of a ketal catalyst, carrying out ketal reaction on the compound as shown in the formula II and a carbonyl protection reagent to obtain a ketal substance; in the presence of an acidic catalyst, carrying out a rearrangement reaction on the ketal to obtain a compoundas shown in a formula IV; under an acidic or alkaline condition, carrying out hydrolysis reaction to obtain a compound as shown in a formula V; under the action of a diazotization catalyst and a phasetransfer catalyst, mixing a compound as shown in a formula V, benzene and nitrite under an acid condition, carrying out diazotization reaction, and carrying out hydrolysis reaction after the diazotization reaction is finished, so as to obtain the corresponding product flurbiprofen as shown in a formula I. The method has the effects of high reaction safety and high yield.

Preparation of optically pure flurbiprofen via an integrated chemo-enzymatic synthesis pathway

In the synthesis of chiral molecules, the incorporation of enantioselective enzymatic conversions within the synthetic route often presents a useful approach. For the substitution of a chemical step with an enzymatic reaction, however, the complete synthetic route leading to and from this reaction needs to be considered carefully. An integrated approach, taking the possibilities and challenges of both types of conversions into account, can give access to chemo-enzymatic processes with great potential for effective synthesis strategies. We here report on the synthesis of enantiopure flurbiprofen using arylmalonate decarboxylase (AMDase, EC 4.1.1.76) in a chemo-enzymatic approach. Interestingly, practical considerations required shifting the enzymatic step to an earlier position in the synthetic route than previously anticipated. Engineered enzyme variants made it possible to obtain both (R)- and (S)-enantiomers of the target compound in excellent optical purity (>99%ee). The presented results underline that enzymes are most useful when they fit in a synthetic route, and that the optimization of biocatalytic steps and the planning of synthetic routes should be an integrated process.

PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular ltk activity.

Novel styrene derivatives of the general formula

Novel styrene derivatives of the general formula STR1 wherein X is hydrogen or halogen, X1 is halogen, R is hydrogen or methyl, Y is hydroxymethyl, carboxyl, --COOR1 or --COR2 wherein R1 is prenyl, geranyl, farn